Canadian Markets open in 4 hrs 47 mins

Titan Pharmaceuticals, Inc. (TTNP)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.00+0.05 (+2.56%)
At close: 3:59PM EDT
People also watch
VNDABDSIIMUCONCSNAVB
Full screen
Previous Close1.95
Open2.00
Bid1.90 x 300
Ask3.05 x 200
Day's Range1.91 - 2.00
52 Week Range1.75 - 6.40
Volume58,773
Avg. Volume154,579
Market Cap42.41M
Beta1.51
PE Ratio (TTM)15.87
EPS (TTM)0.13
Earnings DateMay 11, 2017 - May 12, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • Titan Pharmaceuticals and Walter Reed Army Institute of Research Collaborate to Evaluate ProNeura Antimalarial Implants
    PR Newswire18 days ago

    Titan Pharmaceuticals and Walter Reed Army Institute of Research Collaborate to Evaluate ProNeura Antimalarial Implants

    SOUTH SAN FRANCISCO, Calif., July 6, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with Walter Reed Army Institute of Research (WRAIR) and Southwest Research Institute (SwRI) to evaluate the development of ProNeura-based implants for a long-term regimen in the prevention of malaria.

  • Fortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology
    PR Newswire25 days ago

    Fortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology

    The article discusses how "pharmaceutical implants, matchstick-size devices that deliver drugs to patients over a period of weeks or months, are coming into their own." Specifically, the article highlights Titan's FDA-approved Probuphine® (buprenorphine) implant product, which treats opioid addiction by providing continuous doses of buprenorphine for up to six months, and that is being commercialized in the United States by its partner, Braeburn Pharmaceuticals, as well as Titan's development of its ProNeura implantable technology for Parkinson's disease.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of TTNP earnings conference call or presentation 10-May-17 8:15pm GMT

    Q1 2017 Titan Pharmaceuticals Inc Earnings Call